Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haripriya Andanamala

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
World Journal of Oncology|May 16, 2022
Hemophagocytic Lymphohistiocytosis Secondary to Immune Checkpoint Inhibitor TherapyPramuditha Rajapakse, Haripriya Andanamala
Leukemia Research Reports|November 20, 2024
Challenges and practical considerations in the management of blastic plasmacytoid dendritic cell neoplasm: A single-center experienceHaripriya Andanamala, Naveen Pemmaraju, Taha Al-Juhaishi
Transfusion Medicine (Oxford, England)|January 27, 2023
A second look at the mortality in thrombotic thrombocytopenic purpura score: An external validation studyHaripriya Andanamala, Nichole Brunton, Rima Pai, et al.
International Anesthesiology Clinics|January 21, 2026
Patient Blood Management in Cancer SurgeryKenichi A Tanaka, Haripriya Andanamala, Amir Butt, et al.
JHEP Reports : Innovation in Hepatology|February 12, 2026
Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real studyCiro Celsa, Tiziana Pressiani, Naoshi Nishida, et al.
European Journal of Cancer (Oxford, England : 1990)|April 24, 2026
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinomaPei-Chang Lee, Alessio Cortellini, Bernardo Stefanini, et al.
The Lancet. Digital Health|February 13, 2026
The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort studyMathew Vithayathil, Giulia Francesca Manfredi, Antonio D'Alessio, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
World Journal of Oncology|May 16, 2022
Hemophagocytic Lymphohistiocytosis Secondary to Immune Checkpoint Inhibitor TherapyPramuditha Rajapakse, Haripriya Andanamala
Leukemia Research Reports|November 20, 2024
Challenges and practical considerations in the management of blastic plasmacytoid dendritic cell neoplasm: A single-center experienceHaripriya Andanamala, Naveen Pemmaraju, Taha Al-Juhaishi
Transfusion Medicine (Oxford, England)|January 27, 2023
A second look at the mortality in thrombotic thrombocytopenic purpura score: An external validation studyHaripriya Andanamala, Nichole Brunton, Rima Pai, et al.
International Anesthesiology Clinics|January 21, 2026
Patient Blood Management in Cancer SurgeryKenichi A Tanaka, Haripriya Andanamala, Amir Butt, et al.
JHEP Reports : Innovation in Hepatology|February 12, 2026
Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real studyCiro Celsa, Tiziana Pressiani, Naoshi Nishida, et al.
European Journal of Cancer (Oxford, England : 1990)|April 24, 2026
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinomaPei-Chang Lee, Alessio Cortellini, Bernardo Stefanini, et al.
The Lancet. Digital Health|February 13, 2026
The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort studyMathew Vithayathil, Giulia Francesca Manfredi, Antonio D'Alessio, et al.
Pageof 1